Metrics of salbutamol use as predictors of future adverse outcomes in asthma
Clinical & Experimental Allergy2013Vol. 43(10), pp. 1144–1151
Citations Over TimeTop 11% of 2013 papers
Mitesh Patel, Janine Pilcher, Helen K. Reddel, Alison Pritchard, Andrew Corin, C Helm, Christopher Tofield, Dominick Shaw, Peter Black, Mark Weatherall, Richard Beasley
Abstract
Electronically recorded frequency of current salbutamol use is a strong predictor of risk of future adverse outcomes in asthma, with average daily use performing the best. These findings provide new information for clinicians considering metrics of salbutamol as predictors of future adverse outcomes in asthma.
Related Papers
- → One-year safety and efficacy of budesonide/formoterol in a single inhaler (Symbicort® Turbuhaler®) for the treatment of asthma(2003)80 cited
- → An economic evaluation of combination treatment with budesonide and formoterol in patients with mild-to-moderate persistent asthma(2004)24 cited
- → Asthma control with ICS-formoterol reliever versus maintenance ICS and SABA reliever therapy: a post hoc analysis of two randomised controlled trials(2022)5 cited
- → Safety of Budesonide and Formoterol Administered Via One Pressurized Metered-dose Inhaler (Budesonide/Formoterol pMDI) in Patients (≥12 Years) With Moderate to Severe Persistent Asthma(2007)2 cited
- → Budesonide-Formoterol as Needed for The Treatment of Mild Persistent Asthma(2021)